Plasma p-tau181, Aβ1-42, and GFAP across Alzheimer’s disease, mixed-type Alzheimer’s disease, mild cognitive impairment, anxiety disorders, and depressive disorders
Brain Research · 2027-01 · 1895 · 150606
DOI: 10.1016/j.brainres.2026.150606 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Research, 2027-01. Verfasst von Haifeng Lou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory, Affiliated Mental Health Center & Hangzhou Seventh People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhe…. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Province Basic Public Welfare Research Program.
Themen: Demenz
Abstract (Originalsprache)
BACKGROUND: Blood-based biomarkers including phosphorylated tau181 (p-tau181), amyloid β1-42 (Aβ1-42), and glial fibrillary acidic protein (GFAP) have been widely investigated for Alzheimer's disease (AD) detection. However, their utility for discriminating neurodegenerative cognitive impairment from anxiety and depressive disorders remains poorly established. AIMS: To compare plasma p-tau181, Aβ1-42, and GFAP concentrations across clinically-defined patient groups with AD, mixed-type Alzheimer's disease (MAD), mild cognitive impairment (MCI), anxiety disorders (ANX), and depressive disorders (DEP), and to explore their discriminative performance within this cohort. METHODS: We recruited 287 participants: AD (n = 80), MAD (n = 41), MCI (n = 54), ANX (n = 53), and DEP (n = 59). Plasma concentrations of p-tau181, Aβ1-42 and GFAP were quantitatively measured using magnetic microparticle chemiluminescence immunoassay. We evaluated inter-group biomarker differences as well as associations between biomarker levels and cognitive performance. RESULTS: Plasma p-tau181, Aβ1-42, and GFAP concentrations differed significantly across the five diagnostic groups. In the pooled cohort, all three biomarkers showed inverse associations with MMSE scores, although within-group correlations were weaker and inconsistently significant across diagnostic subgroups. ROC analyses showed that p-tau181 and GFAP had numerically higher AUC values than Aβ1-42 in several pairwise comparisons involving AD or MAD and other clinical groups. CONCLUSIONS: Plasma p-tau181, Aβ1-42, and GFAP showed distinct concentration profiles across the clinically-defined diagnostic groups in this exploratory cross-sectional cohort. GFAP and p-tau181 showed moderate-to-good discriminative performance in several pairwise comparisons involving AD or MAD, whereas Aβ1-42 showed comparatively lower standalone discriminative performance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Laboratory, Affiliated Mental Health Center & Hangzhou Seventh People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Department of Laboratory, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China.
- Department of Laboratory, Affiliated Mental Health Center & Hangzhou Seventh People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. Electronic address: hzqywdk@163.com.
Förderung
- Zhejiang Province Basic Public Welfare Research Program
Zitieren
APA
Lou, H., Huang, C., Shen, J., & Wang, D. (2027). Plasma p-tau181, Aβ1-42, and GFAP across Alzheimer’s disease, mixed-type Alzheimer’s disease, mild cognitive impairment, anxiety disorders, and depressive disorders. Brain Research, 1895, 150606. https://doi.org/10.1016/j.brainres.2026.150606
Vancouver
Lou H, Huang C, Shen J, Wang D. Plasma p-tau181, Aβ1-42, and GFAP across Alzheimer’s disease, mixed-type Alzheimer’s disease, mild cognitive impairment, anxiety disorders, and depressive disorders. Brain Research. 2027;1895:150606. doi:10.1016/j.brainres.2026.150606
BibTeX
@article{Lou2027,
author = {Lou, Haifeng and Huang, Chenyun and Shen, Ji and Wang, Dake},
title = {Plasma p-tau181, Aβ1-42, and GFAP across Alzheimer’s disease, mixed-type Alzheimer’s disease, mild cognitive impairment, anxiety disorders, and depressive disorders},
journal = {Brain Research},
year = {2027},
volume = {1895},
pages = {150606},
doi = {10.1016/j.brainres.2026.150606}
}
EUVIMED